Showing all 2 results
-
Peripheral T-cell lymphoma (PTCL)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Mellalta’s analysts estimate that the United States market is expected to show rapid growth, mainly attributed to, the launch of Adcetris in the front-line setting and expected approval of the potential therapies in the pipeline during the forecast period (2021-2030). Through this, the market size is set to show an extensive jump and grow at a CAGR of 15.3%
-
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022
$2,700.00 – $8,100.00Anti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
Product Search
Filter by price
Top rated products
Product categories
- Hematology 2
- Market Forecast 16
- Respiratory Diseases 1
- Ophthalmology 1
- Orthopedics 1
- Central Nervous System 7
- Inflammatory 1
- Genetic Disorders 1
- Renal Diseases / Nephrology 6
- Endocrinology 1
- Pipeline Analytics Report 1
- Disease Competitive Landscape Monitoring 1
- Metabolic Disorders 1
- Therapeutic Area 18
- Musculoskeletal Diseases 1
- Oncology 2